NCT03065387: Study of the Pan-ERBB Inhibitor Neratinib Given in Combination With Everolimus, Palbociclib or Trametinib in Advanced Cancer Subjects With EGFR Mutation/Amplification, HER2 Mutation/Amplification or HER3/4 Mutation

NCT03065387
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: EGFR, HER2, HER3, HER+4, RAS
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Serine-Threonine Kinase Inhibitor, Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Must have EGFR, RAS, HER2, HER3, and/or HER+4 somatic mutation or EGFR and/or HER2 gene amplification
Exclusions: Known active central nervous system (CNS) metastases- see trial for details
https://ClinicalTrials.gov/show/NCT03065387

Comments are closed.

Up ↑